Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

JAMA Editor’s Summary

Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the

January 3, 2017

Listen on your favorite player Take me to this show’s page

Newer →

The global burden of hypertension, etelcalcetide for secondary hyperparathyroidism, folate for neural tube defect prevention, and more

← Older

Mental health in resource-poor settings, management of new-onset seizures, intra-articular corticosteroids for knee OA, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Biosimilar therapy for breast cancer, zoledronic acid for bone metastases, the future of Obamacare under Donald Trump, and more

Editors’ Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor of JAMA, the Journal of the American Medical Association, for the January 3, 2017 issue

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00